The 2025 Death of Mei: How a Chinese Gene-Editing Trial Ended in Tragedy and Concealment

Key Events: What Happened to Mei

Mei had Snijders Blok-Campeau syndrome, a rare genetic neurodevelopmental disorder that causes developmental delay and cognitive impairment but is not life-threatening . Her case was described as mild .

On or around March 24, 2025, she became the first person in the world to receive a brain-targeted gene-editing therapy. The procedure involved a spinal infusion containing trillions of viral vectors carrying a CRISPR-based base editor designed to correct the underlying genetic mutation .

Within days, Mei developed a fever, stopped producing urine, and experienced a severe drop in platelets. The hospital later listed the cause of death as thrombotic microangiopathy—the formation of deadly microscopic clots—triggered by a severe immune reaction (a cytokine storm) in response to the viral vectors . She died approximately seven days after the infusion .

Mei's parents, identified as "Jason" and "Linda," paid more than $860,000 to fund the development and administration of the therapy, a "pay-to-play" arrangement that was not disclosed in the subsequent Nature paper . According to family accounts, the risks—including the possibility of death—were downplayed by the medical team .

The Concealment: What Was Hidden

The most serious breach involves the publication record. In January 2025—before Mei's death—lead neuroscientist Zilong Qiu submitted a manuscript to Nature describing the animal-study results that underpinned the human trial . After Mei's death, the paper was revised and published in February 2026 in Nature (Volume 651, pages 785–795). It made no mention of Mei, the clinical trial, her death, the family's financial contribution, or the alarming safety signals from the primate studies .

The family asked Qiu not to publish the paper after Mei's death, according to reports . Qiu proceeded regardless.

The trial was also never registered on ClinicalTrials.gov (the U.S. National Institutes of Health database) or the Chinese Clinical Trial Registry . It was conducted under an "investigator-initiated trial" (IIT) framework at a single hospital, which required approval only from Xinhua Hospital's internal ethics committee—not from China's National Medical Products Administration (NMPA), the national drug regulator .

Alarming Safety Signals That Were Ignored

Preclinical primate studies had already raised serious red flags. In non-human primate experiments, three out of four monkeys injected with the same treatment developed severe adverse reactions and had to be euthanized . Those results were not adequately communicated to Mei's parents before the procedure .

Additionally, the dose administered to Mei exceeded the range supported by the available preclinical data . Despite all of this, the trial proceeded in a human child.

Ethical Breaches: A Systematic Failure

• Omission of a fatal adverse event from a major scientific paper. This is a direct violation of standard publication ethics and clinical trial transparency obligations .
• Concealment from regulators and registries. The trial bypassed both international and national oversight mechanisms entirely .
• Financial exploitation of a vulnerable family. Mei's parents paid over $860,000, creating a fundamental conflict of interest—the researchers had a financial incentive to proceed regardless of safety .
• Ignoring clear animal safety data. Proceeding after three of four monkeys had to be euthanized represents a catastrophic failure of risk assessment .
• Lack of informed consent. The family says they were not adequately informed about the risks, including the primate deaths and the possibility of a fatal immune reaction .

Institutional Response

Shanghai Jiao Tong University School of Medicine, which oversees Xinhua Hospital, announced on July 26, 2026, that it had formed a special working group to conduct a "comprehensive investigation" and promised "serious action" based on its findings .

As of late July 2026, Zilong Qiu had not been suspended or removed from his position .

Local district health authorities fined Xinhua Hospital approximately $3,600 for failing to properly oversee the trial .

Broader Implications

Comparisons to He Jiankui

The parallels to the 2018 scandal are stark. In both cases, Chinese researchers operated outside established regulatory frameworks, prioritized speed and prestige over patient safety, and caused severe damage to China's standing in the international biomedical community . Experts quoted by sources say this second major gene-editing scandal demonstrates that the systemic failure that allowed He Jiankui to operate has not been fixed .

Calls for Regulatory Reform

The case has intensified demands from international ethicists and Chinese scientists alike for :

• Mandatory registration of all human gene-editing trials in a public database
• Independent national-level review before any first-in-human gene therapy proceeds
• Clear penalties for concealing adverse events in published research
• Separation of investigator-initiated trials from the "pay-to-participate" model

Damage to Trust in Chinese Biomedical Research

Coming less than a decade after He Jiankui, this second scandal has further eroded trust in China's biomedical oversight. International journals and regulators are likely to impose stricter scrutiny on Chinese gene-therapy trials going forward . The case also raises fundamental questions about the investigator-initiated trial (IIT) framework in China, which allowed a first-in-human brain gene-editing experiment to proceed without national regulatory approval .

The Unanswered Questions

As of late July 2026, several critical questions remain unanswered. Will the Nature paper be retracted or corrected? Will Zilong Qiu face professional consequences beyond an internal university investigation? Will China's regulatory system for investigator-initiated trials be reformed to prevent a similar tragedy? And perhaps most pressingly for other desperate families: how many similar unreported trials are ongoing in China's rapidly expanding biomedical research sector?